1.82% -0.59

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TEVA Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie

Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm

Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial - Benzinga

Assessing Teva Pharmaceutical Industries (TEVA) Valuation After A Sharp Multi‑Month Share Price Rally - Sahm

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - Sahm

Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 49% One Year Share Price Jump - Sahm

Teva stock hits 52-week high at $32.02 - Investing.com

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm

Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound - Sahm

Top 2 Health Care Stocks That May Crash In Q1 - Sahm

Teva Pharmaceutical (ADR) Is Popping Off: Smart Buy or Overhyped Trap? - AD HOC NEWS

Teva Pharmaceutical (ADR): Bracing For 2026 After A Volatile Year Of Legal Wins, Debt Cuts And A Re- - AD HOC NEWS

The Truth About Teva Pharmaceutical (ADR): Is This ‘Boring’ Stock Quietly Going Viral with Inves - AD HOC NEWS

The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS

What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz

Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz

Teva Pharma stock hits 52-week high at 30.45 USD By Investing.com - Investing.com Australia

Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India

Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm

Teva Releases Q4 2025 Aide Memoire - Sahm

Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm

Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm

Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria

Teva Pharma stock hits 52-week high at 29.81 USD - Investing.com

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Teva stock hits 52-week high at 26.38 USD - Investing.com

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz

Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria

Teva Pharma stock hits 52-week high at $25.96 - Investing.com

Simile a TEVA